P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. 2010

Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
National Chromatographic R&A Center, CAS Key Laboratory of Separation Sciences for Analytical Chemistry,Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Dalian 116023, China.

Multidrug resistance (MDR), which is related to cancer chemotherapy, tumor stem cells, and tumor metastasis, is a huge obstacle for the effective cancer therapy. One of the underlying mechanisms of MDR is the increased efflux of anticancer drugs by overexpressed P-glycoprotein (P-gp) of multidrug resistant cells. In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. The resulting Ap-SWNTs could not only specifically recognize the multidrug resistant human leukemia cells (K562R), but also demonstrate the effective loading and controllable release performance for Dox toward the target K562R cells by exposing to near-infrared radiation (NIR). The recognition capability of Ap-SWNTs toward the K562R cells was confirmed by flow cytometry (FCM) and confocal laser scanning microscopy (CLSM). The binding affinity of Ap-SWNTs toward drug-resistant K562R cells was ca. 23-fold higher than that toward drug-sensitive K562S cells. Additionally, CLSM indicated that Ap-SWNTs could specifically localize on the cell membrane of K562R cells and the fluorescence of Dox in K562R cells could be significantly enhanced after the employment of Ap-SWNTs as carrier. Moreover, the composite of Dox and Ap-SWNTs (Dox/Ap-SWNTs) expressed 2.4-fold higher cytotoxicity and showed the significant cell proliferation suppression toward K562R leukemia cells (p < 0.05) as compared with free Dox which is popularly employed in clinic trials. These results suggest that the Ap-SWNTs are the promising drug delivery vehicle for overcoming the MDR induced by the overexpression of P-gp on cell membrane. Ap-SWNTs loaded with drug molecules could be used to suppress the proliferation of multidrug resistant cells, destroy the tumor stem cells, and inhibit the metastasis of tumor.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D042541 Intracellular Space The area within CELLS. Subcellular Space,Intracellular Spaces,Space, Intracellular,Space, Subcellular,Spaces, Intracellular,Spaces, Subcellular,Subcellular Spaces
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D020014 K562 Cells An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS. Cells, K562

Related Publications

Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
December 1987, Japanese journal of cancer research : Gann,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
August 1993, Current opinion in cell biology,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
May 2002, International journal of cancer,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
April 2000, International journal of clinical pharmacology and therapeutics,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
November 1994, Blood,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
August 1998, Leukemia research,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
May 1997, Nihon rinsho. Japanese journal of clinical medicine,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
April 2008, Acta pharmacologica Sinica,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
November 2013, Anticancer research,
Ruibin Li, and Ren'an Wu, and Liang Zhao, and Minghuo Wu, and Ling Yang, and Hanfa Zou
August 2016, Oncology letters,
Copied contents to your clipboard!